|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Thoracic Surgery, City of Hope National Medical Center, 1500 East Duarte Rd, Duarte, CA 91010
(Email: fgrannis@coh.org).
| The first 20% of the full text of this article appears below. |
To the Editor:
Cerfolio and colleagues [1] presented provocative results of surgical treatment in an important subset of stage IIIA nonsmall cell lung cancer (NSCLC) patients with clinically evident, but "non-bulky," and potentially resectable N2 disease. I am puzzled why the authors do not appear to trust their findings and are hesitant to explore the implications of their data.
Their survival curve of 253 patients treated with chemoradiation alone seems to show that all patients died. The curve reaches baseline at zero just beyond 6 years. This is a startling result. Prospective, randomized series suggest that long-term survival in stage
Related Article
Ann. Thorac. Surg. 2009 87: 1320-1321.
This article has been cited by other articles:
![]() |
R. J. Cerfolio Reply Ann. Thorac. Surg., April 1, 2009; 87(4): 1320 - 1321. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |